Summary of clinical features of 29 non-APL AML patients
| Patient . | IL1RAP L/I/H . | Sample . | Age . | Sex . | Diagnosis . | FAB . | Hb (g/L) . | WBC (109/L) . | TPK (109/L) . | BM blast (%) . | PB blast (%) . | Karyotype . | Molecular aberrations . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NPM1 . | FLT3-ITD . | FLT3-TKD . | |||||||||||||
| AML 1 | L | BM | 70 | F | t-AML | M2 | 87 | 8.8 | 58 | 79 | 47 | NK | ND | − | − |
| AML 2 | L | BM | 78 | M | De novo | M2 | 91 | 16 | 68 | 58 | 75 | 41×,-Y,add(5)(q11),der(7)t(7;15) (p11;q11),del(12)(p12),+13,-14,-15,-16,-17,-18[16]/41,idem,-11,+mar[6]/46XY[2] | ND | ND | ND |
| AML 3 | L | BM | 66 | F | De novo | 108 | 313 | 60 | 29 | 24 | NK | − | − | − | |
| AML 4 | L | BM | 61 | F | De novo | M1 | 84 | 2.3 | 7 | 30 | 7 | NK | − | − | − |
| AML 5 | L | BM | 73 | M | De novo | M2 | 99 | 0.2 | 33 | 67 | 54 | 42-43×,-Y,add(1)(p36),-2,add(3)(p21),add(3)(q2?),del(5)(q13q33),-8,add(9)(p11),-10,der(10)(10,10)(q24;q11),?add(11)(q11),-13,-17,-17,-18,?add(19)(q13),-20,-21,+6mar,inc[cp15]/86,idemx2[cp2]/46XY,del(5)(q13q33)[1] | ND | ND | ND |
| AML 6 | L | BM | 67 | F | De novo | 99 | 3.4 | 229 | 25 | 25 | 46XX,t(8;21)(q22;q23)[13]/46XX[12] | ND | ND | ND | |
| AML 7 | I | BM | 57 | F | De novo | 56 | 17 | 244 | 52 | 24 | 45,XX-7[23]/46XX[1] | − | − | − | |
| AML 8 | I | BM | 74 | F | De novo | 94 | 1.5 | 143 | 77 | NK | − | − | − | ||
| AML 9 | I | BM | 36 | M | De novo | M4 | 83 | 19 | 26 | 28 | 21 | 46,XY t(8:21)(q22;q22)[16] /45,idem,-Y[9] | ND | − | − |
| AML 10 | I | BM | 65 | M | De novo | M1 | 77 | 3.7 | 51 | 50 | 60 | 36-43XY,5,del(7)(q22),r?(10), add(12)(p11),-17,add(19)(p13),-20,-21[cp7] | ND | ND | ND |
| AML 11 | I | PB | 72 | F | De novo | M4 | 87 | 155 | 70 | 50 | 62 | NK | ND | − | + |
| AML 12 | I | BM | 85 | M | De novo | 111 | 31 | 91 | 95 | 45,XY,del(5)(q13),der(7)add(7)(q32),-17,idic(19)(p11)[9]/44,idem,-18(3)/45,idem,add(20(q13)[2]/44,idem,-18,add(20)(q13)[11] | ND | ND | ND | ||
| AML 13 | I | BM | 62 | M | De novo | M2 | 102 | 13 | <10 | 65 | 46,XY,del(9)(q22)[7]/46XY[18] | ND | − | − | |
| AML 14 | I | BM | 71 | F | M5 | 118 | 31 | 86 | 70 | 35 | NK | − | − | − | |
| AML 15 | I | BM | 53 | M | De novo | M5 | 113 | 11 | 76 | 70 | 45 | 46,XY,t(9;11)(p21;q23)[14] /47,idem,+19[4]/46XY[2] | − | − | − |
| AML 16 | I | BM | 62 | F | De novo | M2 | 98 | 18 | 127 | 55 | 70 | 46XX, del(5)(q31)[7]/46XX[18] | ND | − | − |
| AML 17 | I | PB | 80 | M | De novo | M1 | 74 | 92.8 | 27 | 60-70 | 78 | NK | ND | ND | ND |
| AML 18 | H | PB | 68 | F | De novo | M1 or M4 | 104 | 136 | 70 | 90 | 72 | 46,XX, inv(9)(p11q12)[22] | ND | + | − |
| AML 19 | H | BM | 55 | F | MDS/AML | M4 | 102 | 19.5 | 116 | 48 | 2,3 | NK | + | + | − |
| AML 20 | H | PB | 74 | M | De novo | M4 | 97 | 15 | 34 | 25 | 8 | No mitoses | + | ND | − |
| AML 21 | H | PB | 77 | F | De novo | M1 | 114 | 66 | 75 | 89 | 90 | NK | + | − | − |
| AML 22 | H | PB | 42 | F | De novo | M4 | 103 | 66 | 33 | 40+27 monocytes | 17+35 monocytes | NK | + | − | − |
| AML 23 | H | BM | 75 | F | De novo | M1 | 110 | 67 | 48 | 94 | 95 | NK | ND | ND | ND |
| AML 24 | H | PB | 40 | M | De novo | 84 | 7.3 | 25 | 60 | 75 | 47,XY,+4[2] /47,XY,+18[2]/46XY[20] | + | − | − | |
| AML 25 | H | BM | 50 | F | De novo | M4 Eo | 51 | 59 | 16 | 19+20 monocytes | 45 | 46,XX,inv(16)(p13q22)[23] /46XX[1] | − | ND | ND |
| AML 26 | H | BM | 81 | F | De novo | M4 | 79 | 124 | 41 | 39 | 82 | NK | + | + | − |
| AML 27 | H | PB | 65 | F | De novo | M4/M5 | 97 | 94 | 32 | 73 | 70 | 47XX,+8[21]/46XX[4] | + | − | − |
| AML 28 | H | BM | 32 | M | De novo | M2 | 37 | 11.5 | 18 | 35 | 50 | 45×,-Y,t(8;21)(q22;q22)[25] | ND | ND | ND |
| AML 29 | H | BM | 74 | M | De novo | M0 | 70 | 143 | 80 | 92 | 75 | 47XY,+13[20]/94,idemx2[25] | ND | ND | ND |
| Patient . | IL1RAP L/I/H . | Sample . | Age . | Sex . | Diagnosis . | FAB . | Hb (g/L) . | WBC (109/L) . | TPK (109/L) . | BM blast (%) . | PB blast (%) . | Karyotype . | Molecular aberrations . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NPM1 . | FLT3-ITD . | FLT3-TKD . | |||||||||||||
| AML 1 | L | BM | 70 | F | t-AML | M2 | 87 | 8.8 | 58 | 79 | 47 | NK | ND | − | − |
| AML 2 | L | BM | 78 | M | De novo | M2 | 91 | 16 | 68 | 58 | 75 | 41×,-Y,add(5)(q11),der(7)t(7;15) (p11;q11),del(12)(p12),+13,-14,-15,-16,-17,-18[16]/41,idem,-11,+mar[6]/46XY[2] | ND | ND | ND |
| AML 3 | L | BM | 66 | F | De novo | 108 | 313 | 60 | 29 | 24 | NK | − | − | − | |
| AML 4 | L | BM | 61 | F | De novo | M1 | 84 | 2.3 | 7 | 30 | 7 | NK | − | − | − |
| AML 5 | L | BM | 73 | M | De novo | M2 | 99 | 0.2 | 33 | 67 | 54 | 42-43×,-Y,add(1)(p36),-2,add(3)(p21),add(3)(q2?),del(5)(q13q33),-8,add(9)(p11),-10,der(10)(10,10)(q24;q11),?add(11)(q11),-13,-17,-17,-18,?add(19)(q13),-20,-21,+6mar,inc[cp15]/86,idemx2[cp2]/46XY,del(5)(q13q33)[1] | ND | ND | ND |
| AML 6 | L | BM | 67 | F | De novo | 99 | 3.4 | 229 | 25 | 25 | 46XX,t(8;21)(q22;q23)[13]/46XX[12] | ND | ND | ND | |
| AML 7 | I | BM | 57 | F | De novo | 56 | 17 | 244 | 52 | 24 | 45,XX-7[23]/46XX[1] | − | − | − | |
| AML 8 | I | BM | 74 | F | De novo | 94 | 1.5 | 143 | 77 | NK | − | − | − | ||
| AML 9 | I | BM | 36 | M | De novo | M4 | 83 | 19 | 26 | 28 | 21 | 46,XY t(8:21)(q22;q22)[16] /45,idem,-Y[9] | ND | − | − |
| AML 10 | I | BM | 65 | M | De novo | M1 | 77 | 3.7 | 51 | 50 | 60 | 36-43XY,5,del(7)(q22),r?(10), add(12)(p11),-17,add(19)(p13),-20,-21[cp7] | ND | ND | ND |
| AML 11 | I | PB | 72 | F | De novo | M4 | 87 | 155 | 70 | 50 | 62 | NK | ND | − | + |
| AML 12 | I | BM | 85 | M | De novo | 111 | 31 | 91 | 95 | 45,XY,del(5)(q13),der(7)add(7)(q32),-17,idic(19)(p11)[9]/44,idem,-18(3)/45,idem,add(20(q13)[2]/44,idem,-18,add(20)(q13)[11] | ND | ND | ND | ||
| AML 13 | I | BM | 62 | M | De novo | M2 | 102 | 13 | <10 | 65 | 46,XY,del(9)(q22)[7]/46XY[18] | ND | − | − | |
| AML 14 | I | BM | 71 | F | M5 | 118 | 31 | 86 | 70 | 35 | NK | − | − | − | |
| AML 15 | I | BM | 53 | M | De novo | M5 | 113 | 11 | 76 | 70 | 45 | 46,XY,t(9;11)(p21;q23)[14] /47,idem,+19[4]/46XY[2] | − | − | − |
| AML 16 | I | BM | 62 | F | De novo | M2 | 98 | 18 | 127 | 55 | 70 | 46XX, del(5)(q31)[7]/46XX[18] | ND | − | − |
| AML 17 | I | PB | 80 | M | De novo | M1 | 74 | 92.8 | 27 | 60-70 | 78 | NK | ND | ND | ND |
| AML 18 | H | PB | 68 | F | De novo | M1 or M4 | 104 | 136 | 70 | 90 | 72 | 46,XX, inv(9)(p11q12)[22] | ND | + | − |
| AML 19 | H | BM | 55 | F | MDS/AML | M4 | 102 | 19.5 | 116 | 48 | 2,3 | NK | + | + | − |
| AML 20 | H | PB | 74 | M | De novo | M4 | 97 | 15 | 34 | 25 | 8 | No mitoses | + | ND | − |
| AML 21 | H | PB | 77 | F | De novo | M1 | 114 | 66 | 75 | 89 | 90 | NK | + | − | − |
| AML 22 | H | PB | 42 | F | De novo | M4 | 103 | 66 | 33 | 40+27 monocytes | 17+35 monocytes | NK | + | − | − |
| AML 23 | H | BM | 75 | F | De novo | M1 | 110 | 67 | 48 | 94 | 95 | NK | ND | ND | ND |
| AML 24 | H | PB | 40 | M | De novo | 84 | 7.3 | 25 | 60 | 75 | 47,XY,+4[2] /47,XY,+18[2]/46XY[20] | + | − | − | |
| AML 25 | H | BM | 50 | F | De novo | M4 Eo | 51 | 59 | 16 | 19+20 monocytes | 45 | 46,XX,inv(16)(p13q22)[23] /46XX[1] | − | ND | ND |
| AML 26 | H | BM | 81 | F | De novo | M4 | 79 | 124 | 41 | 39 | 82 | NK | + | + | − |
| AML 27 | H | PB | 65 | F | De novo | M4/M5 | 97 | 94 | 32 | 73 | 70 | 47XX,+8[21]/46XX[4] | + | − | − |
| AML 28 | H | BM | 32 | M | De novo | M2 | 37 | 11.5 | 18 | 35 | 50 | 45×,-Y,t(8;21)(q22;q22)[25] | ND | ND | ND |
| AML 29 | H | BM | 74 | M | De novo | M0 | 70 | 143 | 80 | 92 | 75 | 47XY,+13[20]/94,idemx2[25] | ND | ND | ND |
The median age of the patients is 67 y of age, which is close to the median age of patients in the Swedish Acute Leukemia Registry. The patients are grouped based on IL1RAP expression: AML1-6 IL1RAP-L,
AML7-17 IL1RAP-I, AML18-29 IL1RAP-H.
APL, acute promyelocytic leukemia; FAB, French-American-British classification system; Hb, hemoglobin; MDS, myelodysplastic syndrome; ND, not determined; NK, normal karyotype; TPK, platelet number; WBC, white blood cells.